{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 4 : Definite"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 4 : Probable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 4 : Possible"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 4 : Unlikely"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 4 : Unrelated"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 3 : Definite"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 3 : Probable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 3 : Possible"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 3 : Unlikely"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Grade 3 : Unrelated"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Grade 2 : Definite"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}],"title":"Grade 2 : Probable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Grade 2 : Possible"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Grade 2 : Unlikely"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"Grade 2 : Unrelated"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Grade 1 : Definite"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74"}]}],"title":"Grade 1 : Probable"},{"categories":[{"measurements":[{"groupId":"OG000","value":"128"}]}],"title":"Grade 1 : Possible"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"Grade 1 : Unlikely"},{"categories":[{"measurements":[{"groupId":"OG000","value":"104"}]}],"title":"Grade 1 : Unrelated"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Adverse events (AEs) are categorized as follows: Treatment-Emergent Adverse Events (TEAEs), which refer to any AEs that arise or worsen in severity after the initiation of treatment with the study product; and Treatment-Related Adverse Events (TRAEs), defined as TEAEs that are considered possibly, probably, or definitely related to the treatment. Adverse Events were graded 1 to 5 via CTAE 4.0 guidelines. All AEs, whether serious or non-serious, will be captured from the time of the first administration of the investigational agent until 30 days following the last dose of study drug or until the initiation of alternative anticancer therapy","groups":[{"description":"cis 75 mg/m2 (SOC), doce 74 mg/m2 (SOC), pembro 200mg (Exp), Q3W IV","id":"OG000","title":"Experimental (Cis/Doce/Pembro)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"first administration of investigational agent until 30 days following last dose of study drug; approximately 3 years and 11 months","title":"Safety and Tolerability of PCD in Patients With Larynx SCC -- Number of Adverse Events","type":"SECONDARY","unitOfMeasure":"adverse events"}